Abstract
In recent years, blood-component therapy has become more accessible in veterinary practice. As with human medicine, care must be taken to minimize the risk of disease transmission from donor to recipient. Determining the appropriate diseases to screen for is complicated by regional variations in disease incidence, the existence of chronic carrier states for some diseases, the difficulty in screening-test selection, and testing cost. The feline diseases considered include retroviral infections, feline coronaviruses, ehrlichiosis ( Ehrlichia canis-like), anaplasmosis ( Anaplasma phagocytophilum), neorickettsiosis ( Neorickettsia risticii), hemoplasmosis ( Mycoplasma hemofelis and M. hemominutum, previously feline hemobartonellosis), and cytauxzoonosis ( Cytauxzoon felis). The canine diseases considered in this paper include babesiosis ( Babesia canis and B. gibsonii,) ehrlichiosis ( E. canis and E. ewingii), anaplasmosis ( A. phagocytophilum), neorickettsiosis ( N. risticii var. atypicalis), leishmaniasis ( Leishmania donovani complex), brucellosis ( Brucella canis), hemoplasmosis ( M. hemocanis, previously canine hemobartonellosis), and bartonellosis ( Bartonella vinsonii).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
